Cambium Bio Limited (ASX:CMB)

Market Cap	11.21M +44.2%
Revenue (ttm)	668.79K -19.1%
Net Income	-3.57M
EPS	-0.16
Shares Out	27.33M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	217
Open	0.4100
Previous Close	0.4100
Day's Range	0.4100 - 0.4100
52-Week Range	0.3450 - 0.6000
Beta	-0.13
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Cambium Bio

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CMB

Financial Performance

In fiscal year 2025, Cambium Bio's revenue was 774,882, an increase of 337.80% compared to the previous year's 176,995. Losses were -3.84 million, 70.4% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 5, 2026

Data Sources Report a data error